Stiris Research Inc. Announces First Patient Enrolled in Phase II Hepatorenal-Syndrome Trial
Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, announces it has enrolled its first patient in a Phase II study in Hepatorenal-Syndrome and Acute Kidney Injury (HRS-AKI).
“I am pleased to announce Stiris’ first enrollment in our Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI) trial. This is a challenging study with a complex patient population that demands consistent and dedicated effort for patient recruitment. We are appreciative of all the work that our sites have dedicated to starting up and enrolling on this trial – they have been pivotal to the success in this trial. We look forward to continued success and future enrollment.” Said Michael Sawras, Project Manager.
Hepatorenal syndrome (HRS) is a form of impaired kidney function that occurs in individuals with advanced liver disease. Individuals with hepatorenal syndrome do not have any identifiable cause of kidney dysfunction and the kidneys themselves are not structural damaged. Blood circulation is abnormal in individuals with hepatorenal syndrome. The arteries that circulate oxygenated blood from the lungs to the rest of the body widen in contrast to the arteries of the kidney, which narrow causing a decrease in the blood flow through the kidney. (https://rarediseases.org/rare-diseases/hepatorenal-syndrome/#:~:text=Hepatorenal%20syndrome%20(HRS)%20is%20a,themselves%20are%20not%20structural%20damaged.)
About Stiris Research
Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.
For more information, please contact: